Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) was $29.03 for the day, up 0.80% from the previous closing price of $28.80. In other words, the price has increased by $0.80 from its previous closing price. On the day, 0.48 million shares were traded. AGIO stock price reached its highest trading level at $29.34 during the session, while it also had its lowest trading level at $28.89.
Ratios:
Our analysis of AGIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.99 and its Current Ratio is at 12.27. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On February 03, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $41.
Goldman Upgraded its Sell to Neutral on November 17, 2022, whereas the target price for the stock was revised from $17 to $32.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 10 ’24 when FOUSE JACQUALYN A sold 7,791 shares for $27.55 per share. The transaction valued at 214,642 led to the insider holds 137,396 shares of the business.
Foster-Cheek Kaye I sold 1,285 shares of AGIO for $40,632 on Mar 07 ’24. The Director now owns 5,524 shares after completing the transaction at $31.62 per share. On Mar 06 ’24, another insider, Foster-Cheek Kaye I, who serves as the Director of the company, sold 4,415 shares for $31.99 each. As a result, the insider received 141,236 and left with 6,809 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 1631335040 and an Enterprise Value of 926404416. For the stock, the TTM Price-to-Sale (P/S) ratio is 60.82 while its Price-to-Book (P/B) ratio in mrq is 2.00. Its current Enterprise Value per Revenue stands at 34.538 whereas that against EBITDA is -2.407.
Stock Price History:
Over the past 52 weeks, AGIO has reached a high of $35.50, while it has fallen to a 52-week low of $19.80. The 50-Day Moving Average of the stock is -0.31%, while the 200-Day Moving Average is calculated to be 14.13%.
Shares Statistics:
AGIO traded an average of 806.78K shares per day over the past three months and 653830 shares per day over the past ten days. A total of 55.95M shares are outstanding, with a floating share count of 54.74M. Insiders hold about 2.59% of the company’s shares, while institutions hold 106.22% stake in the company. Shares short for AGIO as of 1711584000 were 6601368 with a Short Ratio of 8.18, compared to 1709164800 on 7333846. Therefore, it implies a Short% of Shares Outstanding of 6601368 and a Short% of Float of 11.89.
Earnings Estimates
The market rating of Agios Pharmaceuticals Inc (AGIO) is currently shaped by the ongoing analysis conducted by Edgio, Inc. analysts closely monitoring its performance.The consensus estimate for the next quarter is $14.94, with high estimates of $29.03 and low estimates of $116.24.
Analysts are recommending an EPS of between $Healthcare and $Industrials for the fiscal current year, implying an average EPS of $Basic Materials.
